文献速递肺外科

新辅助治疗与T4肺癌纵隔侵犯患者更优结局相关

Neoadjuvant Treatment Is Associated With Superior Outcomes in T4 Lung Cancers With Local Extension.
PubMed 文献 · Ann Thorac Surg · 2020-07-11

该研究基于美国国家癌症数据库(NCDB)2006—2015年1101例临床T4N0/1M0非小细胞肺癌纵隔侵犯患者,比较直接手术与新辅助治疗后手术的切缘状态和总生存。新辅助治疗组切缘阳性率更低(9.3% vs 33.1%),中位总生存更长(65.9 vs 27.5个月);倾向匹配后结果一致。

要点

  • T4N0/1纵隔侵犯肺癌接受新辅助治疗者切缘阳性率显著低于直接手术。
  • 新辅助治疗组中位总生存65.9个月,直接手术组27.5个月。
  • 倾向匹配分析后新辅助治疗仍与更低切缘阳性率和更长生存相关。

核心结论

  • 在NCDB中,T4N0/1纵隔侵犯患者接受新辅助治疗者切缘阳性率更低且总生存更优。
  • 应考虑在这类患者中使用新辅助治疗。

研究设计与样本

  • 回顾性队列研究,使用美国国家癌症数据库2006—2015年临床T4N0/1M0非小细胞肺癌接受肺叶、双肺叶或全肺切除的患者。
  • 共纳入1101例,其中595例(54.0%)接受直接手术,506例(46.0%)接受新辅助治疗。
  • 新辅助治疗定义为术前化疗和/或放疗;放疗后超过120天手术者被排除。
  • 研究终点为病理切缘状态和总生存,并进行1:1倾向匹配分析。

主要发现

  • 新辅助治疗组切缘阳性46/506例(9.3%),直接手术组186/595例(33.1%),P < .001。
  • 多因素分析显示新辅助治疗与更低切缘阳性率相关(OR 0.220,P < .001)。
  • 新辅助治疗组总生存长于直接手术组(65.9 vs 27.5个月,P < .001)。
  • 倾向匹配得到331对患者,新辅助治疗组切缘阳性率10.5% vs 31.3%,P < .001。
  • 匹配队列中新辅助治疗组总生存更优(57.0 vs 27.5个月,P < .001)。

临床怎么用

  • 对临床T4N0/1M0纵隔侵犯的非小细胞肺癌患者,可考虑新辅助化疗和/或放疗后再行手术。
  • 新辅助治疗可能降低切缘阳性风险并改善总生存,应与多学科团队讨论个体化方案。

局限性

  • 研究为基于NCDB的回顾性分析,存在选择偏倚和未测量混杂的可能。
  • 新辅助治疗方案(化疗和/或放疗)未进一步细化,无法区分不同方案的效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neoadjuvant chemoradiation is associated with improved survival of superior sulcus cancers, but little data exists regarding clinical T4 lung cancers with mediastinal invasion. We hypothesized that neoadjuvant treatment would be associated with improved survival in T4 lung cancer patients with mediastinal invasion. METHODS: Clinical T4-N0/1-M0 non-small cell lung cancers from 2006-2015 were identified in the National Cancer Database. Patients with T4 extension to mediastinal structures undergoing lobectomy, bilobectomy, or pneumonectomy were included. Neoadjuvant treatment was defined as preoperative chemotherapy and/or radiation. Patients receiving surgery >120 days after radiation were excluded. Study endpoints were pathologic margin status and overall survival. To adjust for heterogeneity, a 1:1 propensity match analysis was performed. RESULTS: A total of 1101 patients with cT4N0/1M0 cancers were analyzed; 595 (54.0%) received primary surgery and 506 (46.0%) received neoadjuvant treatment. Neoadjuvant therapy was associated with fewer positive surgical margins (46 of 506 [9.3%] vs 186 of 595 [33.1%], P < .001). Multivariate analysis showed an association of neoadjuvant therapy with a lower rate of positive margin (odds ratio 0.220, P < .001). Overall survival was longer among patients receiving neoadjuvant treatment (65.9 vs 27.5 months, P < .001). Propensity matching identified 331 matched pairs of patients. Among these, positive margins were less likely after receiving neoadjuvant treatment (10.5% vs 31.3%, P < .001). Overall survival among the matched pairs was improved in those receiving neoadjuvant treatment (57.0 vs 27.5 months, P < .001). CONCLUSIONS: In the NCDB, T4N0/1 mediastinal invasion patients who receive neoadjuvant treatment have decreased rates of positive surgical margins and improved overall survival. The use of neoadjuvant treatment should be considered in these patients.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Towe CW, Worrell SG, Bachman K, et al. Neoadjuvant Treatment Is Associated With Superior Outcomes in T4 Lung Cancers With Local Extension. Ann Thorac Surg. 2020. PMID: 32663471. doi:10.1016/j.athoracsur.2020.05.084

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。